<DOC>
	<DOCNO>NCT00748072</DOCNO>
	<brief_summary>The investigator evaluate effect pre-biopsy treatment 1-deamino-8-D-arginine ( DDAVP ) incidence post-biopsy bleeding complication . This IV phase single centre , double blind , randomize control study patient , acute chronic nephropathy , undergo ultrasound-guided percutaneous renal biopsy .</brief_summary>
	<brief_title>1-deamino 8-d-arginine Vasopressin ( DDAVP ) Percutaneous Ultrasound-guided Renal Biopsy</brief_title>
	<detailed_description>Renal biopsy essential procedure diagnosis primary secondary renal disease . The technique significantly improve past two decade introduction ultrasonography automated-gun biopsy device ; however accurate clinical , chemistry renal ultrasound evaluation 24-hours post renal biopsy necessary , bleed complication still occur 1/3 procedure , major complication occur 1.2 % patient . Of data routinely collect potential predictor post-biopsy bleeding complication , gender , age , baseline partial thromboplastin time show significant predictive value . The variable investigate predictive value ( Manno C et al , Kidney Int 2004 ) . The majority publish study , retrospective non-randomized , topic focus comparative performance different renal biopsy technique type needle , study show potential predictor post-biopsy bleeding complication . On hand , available study show specific test select patient major risk post-biopsy bleeding . The aim study evaluate effect pre-biopsy treatment DDAVP desmopressin incidence post-biopsy bleeding complication . DDAVP synthetic derivative anti-diuretic hormone vasopressin ; therefore , administration DDAVP often accompany water retention , drop blood pressure secondary increase heart rate . The haemostatic effect DDAVP related increase vWF-factor VIII level . DDAVP treatment choice patient von Willebrand ( type I ) disease haemophilia A ; moreover , compound show useful variety inherit acquire hemorrhagic condition , include congenital platelet function defect , chronic liver disease , uremia , haemostatic defect induce therapeutic use anti-thrombotic drug aspirin ticlopidine . Finally , DDAVP use haemostatic agent patient undergo surgery major risk bleeding . Disadvantages DDAVP include report rare thrombotic event .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Diabetes Insipidus</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Arginine Vasopressin</mesh_term>
	<mesh_term>Vasopressins</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>1 . Males females &gt; 16 &lt; 80 year age . 2 . Blood pressure &lt; 140/90 mmHg . 3 . Serum creatinine ≤ 1.5 mg/dl and/or creatinine clearance ≥ 60 ml/min . 4 . Bleeding time , prothrombin time , partial thromboplastin time , platelet fibrinogen normal range . 1 . Biopsy transplant kidney 2 . Poorly control hypertension 3 . Single kidney 4 . Renal cancer 5 . Hydro/pyonephrosis 6 . Renal size significantly reduce 7 . Severe obesity 8 . Coagulation disorder 9 . Serum creatinine &gt; 1.5 mg/dl and/or creatinine clearance &lt; 60 ml/min</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Vasopressin</keyword>
	<keyword>bleeding</keyword>
	<keyword>biopsy</keyword>
	<keyword>ultrasonography</keyword>
</DOC>